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This review summarizes the role of extracellular calcium, as found present in the bone tissue, in the
process of bone metastasis.
& 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The microenvironment of bone tissue is characterized by a
unique composition. Due to the constitutive degradation and re-
building by osteoclasts and osteoblasts it presents a high con-
centration of growth factors and calcium. Tumor cells recognize
extracellular calcium by the calcium-sensing receptor (CaSR) or
the P2X-receptor, and mediate calcium inﬂux or efﬂux through ion
channels and transporters. In renal, breast and prostate cancer,
calcium has been shown to promote bone metastasis via CaSR. In
addition, the ion channels TRPV6 and SK3 have been shown to be
relevant factors in the formation of bone metastasis. This would
implicate that extracellular calcium plays a role in the formation of
bone metastasis via varying routes. This review studies the impact
of extracellular calcium, as found present in bone tissue, on bone
metastasis.is an open access article under the
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er).1.1. The shaping of metastasis through bone microenvironment
As early as 1889, Stephen Paget developed the so-called “seed
and soil” theory, which postulates a highly signiﬁcant importance
of the microenvironment in the secondary site in organ speciﬁc
metastasis [1]. This implicates that different organs have a parti-
cular characteristic (“soil”) which is preferred by metastasizing
tumor cells of speciﬁc feature (“seed”). The bone is an organ with a
unique microenvironment, differing from all other organs of the
body. Due to the circumstance that bone tissue is constitutively
degraded by osteoclasts and rebuilt by osteoblasts, numerous
growth factors and cytokines are released, including transforming
growth factor beta (TGFβ), insulin-like growth factors I and II (IGF I
and II), ﬁbroblast growth factor (FGF) and platelet-derived growth
factors (PDGF), as reviewed by Roodman [2]. Among the high
concentration of these bioactive agents, bone is characterized by a
high concentration of calcium ions. Whereas in peripheral blood
plasma calcium is found present in a concentration range between
2.2 and 2.6 mM, the concentration in bone plasma is around
10 mM, in the extracellular space of bone tissue even around
20 mM [3]. This reﬂects an ever increasing calcium concentration
beginning outwith the bone and progressing to the inner bone
tissue. Extracellular calcium affects cells by various different me-
chanisms: These can be calcium channels as well as calcium
binding proteins. The calcium-sensing receptor (CaSR) is an im-
portant calcium binding receptor in bone tissue, which seems to
be highly signiﬁcant for the formation of bone metastasis.
1.2. Bone metastasis induced by CaSR
The heterodimeric G-protein coupled CaSR is the most im-
portant receptor on the cell surface for detecting extracellularCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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regulation of calcium homeostasis in several organs such as kid-
ney, breast, gastrointestinal tract, bones and parathyroid glands, as
reviewed by Tennakoon et al. [4]. The binding of calcium on CaSR
activates a variety of signaling pathways.
Although CaSR may also have a tumor suppressing capacity in
e.g. gastric and colon cancer [5,6], it has been demonstrated to be
involved in bone metastasis of several tumor entities, such as renal
cell carcinoma, prostate carcinoma and breast cancer. In renal cell
carcinoma tissue from patients developing bone metastases dur-
ing a ﬁve year period after nephrectomy, CaSR was expressed
distinctly higher than in the tissue of patients without bone me-
tastases. This was independent of the development of metastases
in other secondary sites such as the lung, or if the patient re-
mained free of metastases. Primary renal carcinoma cells from
patients with bone metastases showed a similar CaSR expression
and were highly sensitive to calcium treatment concerning cell
proliferation and chemotactical migration directed to enhanced
calcium concentration. The CaSR inhibitor NPS 2143 elucidated the
role of CaSR on the calcium-dependent effects. Signaling pathways
including AKT, phospholipase C γ1 (PLCγ1), p38α, JNK and PTEN
have been identiﬁed as being responsible for the increased me-
tastatic behavior of CaSR-bearing renal cancer cells after calcium
treatment [7].
Saidak et al. also showed a signiﬁcantly higher migratory ca-
pacity in a breast cancer cell line metastasizing into bone (MDA-
MB-231) compared to cells with a lower bone-metastasizing be-
havior (MCF7 and T47D) or cells not metastasizing into bones
(BT474). The involvement of CaSR in these effects was proved by
using CaSR inhibiting siRNA. The ERK1/2 MAPK and PLCβ signaling
pathways have been shown to be involved in these effects [8].
Similar to the situation in healthy renal and breast tissue, CaSR
is also expressed in prostate tissue. Using microarray analysis, Feng
et al. demonstrated a signiﬁcantly higher CaSR expression in pri-
mary prostate cancer tissue from patients with bone metastases
compared to those without bone metastases [9]. This reﬂects theFig. 1. “Vicious cycle”. Calcium and other growth factors trigger the secretion of PTHrP, P
immature osteoblasts, which activates the formation of osteoclasts by precursors. The o
such as PDGF, TGFβ, IGF1 and bone morphogenetic proteins (BMP's) are released.former results that, in contrast to the non-skeletal metastatic
prostate cancer cell line LNCaP, in bone metastatic prostate cancer
cell lines PC-3 and C4-2B CaSR was highly expressed and calcium
treatment induced an enhanced proliferation. As observed in renal
cancer, in prostate cancer the AKT signaling pathway also seems to
be involved in CaSR dependent bone metastasis [10].
Chirgwin and Guise deﬁned a “vicious cycle” in bone metastasis,
activated when metastasizing tumor cells come in contact with
bone tissue. Growth factors such as TGFβ, released during bone
degradation by osteoclasts, stimulate tumor cells to secrete para-
thyroid hormone-related protein (PTHrP), prostaglandin E-2 (PGE-
2) and macrophage colony-stimulating factor (m-CSF), which in-
crease the expression of RANKL (receptor activator of NF-κB li-
gand) on immature osteoblasts [11]. This again activates osteo-
clastogenesis via RANK on osteoclast precursors, leading to en-
hanced osteolysis, resulting in an enhanced secretion of growth
factors and calcium, again activating tumor cells [12]. However,
not only growth factors are able to activate a “vicious cycle”: An
activation of CaSR by calcium also induces a release of PTHrP by
several tumor cells thus facilitating bone metastasis, as reviewed
by Saidak et al. [8]. This process is mediated by the ERK1/2 sig-
naling pathway (Fig. 1) [13]. In prostate cancer, which forms
mostly osteoblastic metastases a similar “vicious cycle” under in-
volvement of prostate speciﬁc antigen (PSA) and endothelin-1 (ET-
1) is suggested [14].
In addition to CaSR, calcium ion channels are also relevant for
the effect of extracellular calcium on cancer cells, thus inﬂuencing
bone metastasis. A selection of calcium ion channels bearing im-
pact in bone metastasis is described below.
1.3. The inducement of bone metastasis through calcium-dependent
ion channels
Calcium ion channels are capable of changing the intracellular
calcium concentration and activating several signaling pathways.
The calcium-selective channel TRPV6 [15] has been shown to playGE-2 and M-CSF in cancer cells. This leads to an increased expression of RANKL on
steoclasts induce enhanced bone degradation, whereby calcium and growth factors
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TRPV6 show highly aggressive behavior. When prostate PC-3 cells
are transfected with the TRPV6 gene and infected into the bone
marrow cavity of the tibia of mice, osteoblastic lesions and en-
hanced formation of bone metastasis occur [16].
Another member of the TRP family, TRPM7, a cation channel
with kinase activity, may also play a role in bone metastasis.
Neuroblastoma cells transfected with TRPM7 highly accumulate in
bone tissue. However, TRPM7 activity seems only to induce cell
migration into bone tissue, but does not seem to stimulate cell
proliferation. This would suggest that bone metastasis formation
reﬂects a combination of several factors [17].
The SK3 channel, a calcium activated potassium channel, has
also been shown to be associated with bone metastasis [18]. In a
complex with Orai1, located in lipid rafts of the cell membrane, it
controls the calcium inﬂux and so regulates cancer cell migration,
leading to the formation of bone metastases. This effect depends
on the cAMP-PKA pathway [19].
Furthermore the P2X-receptor has been discussed as con-
tributor for bone metastasis [20]. Extracellular nucleotides can
trigger a P2X-mediated inﬂux of calcium, thus leading to increased
cell proliferation and survival through the AKT pathway [21].2. Conclusion
Bone metastasis depends on induction of proliferation and less
on tumor cell seeding. The “seed and soil” theory of Paget im-
plicates a balance between the inﬂuence of seeded tumor cells and
of the microenvironment of the secondary organ. However, in
bone tissue the microenvironment seems to be the main inﬂuen-
tial factor in facilitating bone metastasis. In prostate and breast
cancer it is not the number of tumor cells seeded in bone tissue
that affects the development of bone metastases but the growth
supporting microenvironment of the bone, created by bone turn-
over [22]. The revival of dormant cancer cells in the bone tissue
may also be inﬂuenced by changes in the bone microenvironment
since in myeloma cells dormancy was shown to be switched off by
osteoclasts remodeling [23]. However, an effect of calcium in this
process could not be shown. Apart from other bone speciﬁc cy-
tokines and growth factors, calcium is one of the key players in the
formation of bone metastasis and should be taken into con-
sideration when planning therapeutic strategies for preventing
bone metastasis. In other diseases such as chronic obstructive
pulmonary disease (COPD) or allergic asthma, calcilytics inhibiting
CaSR are discussed as new therapeutics [24,25] and could also be
used for preventing bone metastasis. Furthermore, the calcium
mimetic Ra-223, blocking CaSR, is an example of a new bone-
targeted therapy with potent antitumor effects in ﬁrst trials [26].References
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